Boston ups women’s health output with BHN deal
This article was originally published in Clinica
Boston Scientific has signed a four-year exclusive marketing deal with Bladder Health Network (BHN) for the latter’s female urodynamic testing solutions. The collaboration will see Boston’s urology and women’s health division sell BHN’s technology in the US. BHN (Jackson, Mississippi) offers urodynamic testing software, staffing, results analysis tools and other equipment. According to Natick, Massachusetts-based Boston, urinary incontinence affects one in four women in the US. Boston’s women’s health portfolio already includes mid-urethral sling systems designed to treat stress urinary incontinence (SUI), the Coaptite injectable implant for soft tissue augmentation in the treatment of SUI due to intrinsic sphincter deficiency, the Capio PFR kit for the treatment of pelvic floor reconstruction, the Xenform tissue repair matrix for reinforcing soft tissues and the Polyform synthetic mesh for pelvic organ prolapse.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals